ORYZON to Provide Corporate Progress Updates at Several Events in April

• Investing in Oncology Forum 2024
  
• Van Lanschot Kempen Life Sciences Conference
• Swiss Biotech Day 2024
• LSX World Congress

MADRID, Spain and BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in April.

Oryzon has been invited to attend the Investing in Oncology Forum 2024, which will be held at the IVA Konferenscenter in Stockholm (Sweden) on April 10, where the company will provide a corporate update at 14:45 CET and will hold one-on-one meetings with global investors and pharmaceutical companies. Click on the link for more info about the Investing in Oncology Forum 2024

Oryzon will attend the Van Lanschot Kempen Life Sciences Conference, which will take place in Amsterdam (Netherlands) on April 16-17, where the company will maintain meetings with investors. Click on the link for more info about the Van Lanschot Kempen Life Sciences Conference

Oryzon will attend the Swiss Biotech Day 2024, which will be held at the Markthalle in Basel (Switzerland) on April 22-23. The company will hold one-on-one meetings with pharmaceutical companies. Click on the link for more info about the Swiss Biotech Day 2024

Oryzon has been invited to the LSX World Congress 2024, which will be held in London (UK) on April 29-30. Oryzon will take part in the keynote plenary panel entitled “The inflation Reduction Act and its Potential Impact On EU Biotech & Pharma Companies: Demystifying the Future” on April 29 at 16:20 BST. Click on the link for more info about the LSX World Congress 2024

About Oryzon
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon’s team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an advanced clinical portfolio with two LSD1 inhibitors, vafidemstat in CNS and iadademstat in oncology, in several Phase II clinical trials. The company has other pipeline assets directed against other epigenetic targets like HDAC-6, where ORY-4001 has been nominated as clinical candidate for the treatment of certain neurological disorders such as CMT and ALS. In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases. For more information, visit www.oryzon.com